Physician profile
Gregory H Narron
NPI 1043321151
$6,943.68
in general payments reported to CMS, 2019-2025
24 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $504 · 2021: $1,008 · 2022: $1,256 · 2023: $1,576 · 2024: $882 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $826.15 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $722.32 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $465.46 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $443.80 | 2022-2024 | Caplyta |
| Neos Therapeutics, LP | $428.94 | 2019-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $422.06 | 2019-2021 | |
| Lundbeck LLC | $420.41 | 2019-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $415.94 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $387.42 | 2022-2024 | Azstarys |
| Neuronetics, INC. | $246.79 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $207.07 | 2019-2024 | |
| Noven Therapeutics, LLC | $140.66 | 2023-2024 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $140.16 | 2019 | |
| Tris Pharma INC | $132.03 | 2021-2024 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $114.37 | 2021-2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $56.40 | 2019-2021 | |
| Eisai INC. | $47.29 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $45.83 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $42.66 | 2024 | Uzedy |
| Merck Sharp & Dohme LLC | $21.70 | 2021 | |
| Adlon Therapeutics L.P. | $20.74 | 2021 | |
| Alkermes, INC. | $19.03 | 2023 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Narron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.